Login to Your Account

Neurogen Assured $42M, Could Get Much More In Merck Alliance

By Kim Coghill

Tuesday, December 2, 2003
Neurogen Corp.'s stock gained 64 percent Monday on news that it entered an exclusive worldwide alliance with Merck & Co. Inc. to discover and develop pain medications that target the vanilloid receptor, a key integrator of pain signals in the nervous system. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription